project . 2022 - 2024 . Not started

BreaKer

Dissecting how breast cancer-associated inflammation shapes invariant natural killer T cell activity during metastatic progression
Open Access mandate for Publications and Research DataOpen Access mandate for ... European Commission
  • Funder: European CommissionProject code: 101025502 Call for proposal: H2020-MSCA-IF-2020
  • Funded under: H2020 | MSCA-IF-EF-ST Overall Budget: 175,572 EURFunder Contribution: 175,572 EUR
  • Status: Not started
  • Start Date
    01 Sep 2022
    End Date
    31 Aug 2024
  • Detailed project information (CORDIS)
Description
Breast cancer is the second cause of cancer-related death in women. Although cancer immunotherapy emerged as a successful therapy for many cancer types, the response of metastatic breast cancer patients to immune checkpoint blockade remains disappointing, urging for a better understanding of the breast cancer immune landscape. iNKT cells are lipid-specific T cells that bridge innate and adaptive immunity and exert a plethora of immune functions depending on tissue distribution. Despite their known antitumor potential, they have been largely overlooked in the cancer field for their content paucity in cancer patients. I hypothesize that their scarce abundance and ...
Partners
Description
Breast cancer is the second cause of cancer-related death in women. Although cancer immunotherapy emerged as a successful therapy for many cancer types, the response of metastatic breast cancer patients to immune checkpoint blockade remains disappointing, urging for a better understanding of the breast cancer immune landscape. iNKT cells are lipid-specific T cells that bridge innate and adaptive immunity and exert a plethora of immune functions depending on tissue distribution. Despite their known antitumor potential, they have been largely overlooked in the cancer field for their content paucity in cancer patients. I hypothesize that their scarce abundance and ...
Partners
Any information missing or wrong?Report an Issue